Is Severity of Adverse Events Affected by the Dose and Frequency of Glatiramer Acetate Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)?

被引：0
|
作者：
Wu, Y. [1 ]
Gandhi, S. [1 ]
Grinspan, A. [1 ]
Kolodny, S. [2 ]
Zagmutt, F. J. [3 ]
机构：
[1] Teva Pharmaceut Ind, Frazer, PA USA
[2] Teva Pharmaceut Ind, Cleveland, OH USA
[3] EpiX Analyt, Boulder, CO USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-45
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [41] Investigating glatiramer acetate for relapsing–remitting multiple sclerosis at the double dose—is more better?
    Peter A Calabresi
    [J]. Nature Clinical Practice Neurology, 2007, 3 : 540 - 541
  • [42] A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Howard Zwibel
    Gabriel Pardo
    Shelly Smith
    Douglas Denney
    MerriKay Oleen-Burkey
    [J]. Journal of Neurology, 2011, 258 : 402 - 411
  • [43] A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Zwibel, Howard
    Pardo, Gabriel
    Smith, Shelly
    Denney, Douglas
    Oleen-Burkey, MerriKay
    [J]. JOURNAL OF NEUROLOGY, 2011, 258 (03) : 402 - 411
  • [44] Treatment of relapsing-remitting multiple sclerosis with glatiramer-acetate:: our 7-year clinical experience
    Hradilek, P.
    Zapletalova, O.
    Woznicova, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2006, 12 : S98 - S98
  • [45] Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
    Sanchez-de la Rosa R.
    Sabater E.
    Casado M.A.
    [J]. Health Economics Review, 3 (1) : 1 - 5
  • [46] A longitudinal observational study of a cohort of patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate
    Moreau, T.
    Brudon, F.
    Debouverie, M.
    Heinzlef, O.
    Lebrun-Frenay, C.
    Gury, C.
    [J]. MULTIPLE SCLEROSIS, 2006, 12 : S99 - S99
  • [47] Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis
    Crescenzo, F.
    Marastoni, D.
    Zuco, C.
    Pitteri, M.
    Magliozzi, R.
    Monaco, S.
    Calabrese, M.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 27 : 305 - 311
  • [48] A combination trial of estriol plus glatiramer acetate in relapsing-remitting multiple sclerosis: effect on disabilities
    Voskuhl, R.
    Wang, H.
    Lee, G.
    Giesser, B.
    Tse, C. H.
    Elashoff, R.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 44 - 44
  • [49] Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis
    Khan, O
    Shen, YM
    Caon, C
    Bao, F
    Ching, W
    Reznar, M
    Buccheister, A
    Hu, JN
    Latif, Z
    Tselis, A
    Lisak, R
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (06) : 646 - 651
  • [50] Fingolimod versus glatiramer acetate in patients with relapsing-remitting multiple sclerosis - ASSESS study results
    Cree, B. A.
    Goldman, M. D.
    Corboy, J. R.
    Singer, B.
    Fox, E.
    Arnold, D. L.
    Ford, C.
    Weinstock-Guttman, B.
    Bar-or, A.
    Mientus, S.
    Sienkiewicz, D.
    Zhang, Y.
    Karan, R.
    Tenenbaum, N.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 163 - 163
12345